FDA
Entity.
- Evidence
- 3,442 documents · 277 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 6 Apr 2026, last seen 11 Nov 2026
- Measured
- 36% of mentions say something specific about it; the rest only name it
- As of
- 22 Nov 2026
Where this comes from
- Tech Times · 2026-11-11 · PepGen's Myotonic Dystrophy Drug Sets Phase 2 Efficacy Record: FDA Hold Still Bars American Patients (opens the source in a new tab)
- FDA Drug News · 2026-11-10 · [APPROVAL] FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer (opens the source in a new tab)
- FDA Drug News · 2026-11-10 · [APPROVAL] FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer (opens the source in a new tab)
- FDA Drug News · 2026-11-10 · [APPROVAL] FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer (opens the source in a new tab)
- FDA Drug News · 2026-11-10 · [APPROVAL] FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy (opens the source in a new tab)
- FDA Drug News · 2026-11-10 · [APPROVAL] FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (opens the source in a new tab)
- FDA Drug News · 2026-11-10 · [APPROVAL] FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer (opens the source in a new tab)
- FDA Drug News · 2026-11-10 · [APPROVAL] FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma (opens the source in a new tab)
- FDA Drug News · 2026-11-10 · [APPROVAL] FDA approves nivolumab for adjuvant treatment of Stage IIB/C melanoma (opens the source in a new tab)
- FDA Drug News · 2026-11-10 · [APPROVAL] FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection (opens the source in a new tab)
- FDA Drug News · 2026-11-10 · [APPROVAL] FDA approves new and updated indications for temozolomide under Project Renewal (opens the source in a new tab)
- Food Ingredients First · 2026-11-10 · US FDA revokes authorizations for solvent uses in natural food color manufacturing (opens the source in a new tab)
What is claimed about it
- Corroborated: Reported by three or more sources that did not copy each other.
- Reported by two: Reported by two sources that did not copy each other.
- Single source: Reported by one source so far.
- Could not check: We could not count this claim's sources, so we do not say how well it is supported.
- Capricor’s Duchenne treatment fails to get FDA approval, shares sink Could not check · first reported 20 Nov 2026
- STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming Single source · first reported 20 Nov 2026
- FDA gives nod to Regeneron's Livsayis as first siRNA treatment for generalized myasthenia gravis Single source · first reported 19 Nov 2026
- White House Pulls Heidi Overton's FDA Nomination as Vaccine, Abortion Pill and Vaping Disputes Fuel Senate Opposition Reported by two · first reported 18 Nov 2026
- Sanofi Wins First FDA Approval for Brain-Penetrating Gaucher Drug; South Korea's Yuhan Eyes Once-Monthly Dosing in Follow-On Challenge Reported by two · first reported 18 Nov 2026
- STAT+: FDA discloses reasons for rejecting Summit drug Single source · first reported 18 Nov 2026
- Medtronic Hugo Robot Wins FDA General Surgery Clearance; Only Hernia Repair Has Disclosed US Trial Reported by two · first reported 17 Nov 2026
- FDA issues proposed rule on NAC products as dietary supplements Reported by two · first reported 17 Nov 2026
- Ivonescimab, a Closely Watched Lung Cancer Drug From China, Rejected by FDA Without Significant Survival Gain Corroborated · first reported 16 Nov 2026
- U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as the First Companion Diagnostic in the U.S. for WILSERDLY (giredestrant) in Combination with Everolimus for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer Reported by two · first reported 16 Nov 2026
- Biocon Wins FDA Approval for 420 mg Pebrilzo Breast Cancer Injection Single source · first reported 16 Nov 2026
- Senate health chair unsure if Trump’s FDA pick has support to pass committee’s vote Could not check · first reported 16 Nov 2026